Cancer vaccines: Harnessing the potential of anti-tumor immunity

Veterinary Journal

Volumn 198, Issue 1, 2013, Pages 28-33

  Suckow, Mark A ^a  

^a UNIVERSITY OF NOTRE DAME   (United States)

Author keywords

Cancer; Dog; Immunity; Tumor stroma; Tyrosinase; Vaccine

Indexed keywords

CANCER VACCINE; CYCLOPHOSPHAMIDE; CYTOKINE; EPIDERMAL GROWTH FACTOR RECEPTOR 2; GAMMA INTERFERON; GLYCOPROTEIN GP 100; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR VACCINE; INTERLEUKIN 2; MELANOMA VACCINE; SIPULEUCEL T; TRANSFORMING GROWTH FACTOR BETA; TUMOR ANTIGEN; VASCULOTROPIN; WART VIRUS VACCINE;

ADAPTIVE IMMUNITY; ANTIBODY RESPONSE; ANTIGEN PRESENTING CELL; ANTIGEN RECOGNITION; CANCER IMMUNIZATION; CANCER STEM CELL; CANCER SURVIVAL; CARCINOGENESIS; CELLULAR IMMUNITY; CHILL; CUTANEOUS MELANOMA; CYTOKINE PRODUCTION; CYTOKINE RESPONSE; CYTOTOXIC T LYMPHOCYTE; DENDRITIC CELL; DRUG SAFETY; FEVER; FIBROBLAST; FLU LIKE SYNDROME; HEADACHE; HUMAN; HYPERHIDROSIS; IMMUNOCOMPETENCE; INNATE IMMUNITY; INTERFERON PRODUCTION; LUNG NON SMALL CELL CANCER; MELANOMA; MYALGIA; NATURAL KILLER CELL; NONHUMAN; PROSTATE CANCER; REVIEW; STROMA; SURVIVAL TIME; TUMOR ESCAPE; TUMOR GROWTH; TUMOR IMMUNITY; TUMOR MICROENVIRONMENT; UTERINE CERVIX CANCER;

CANIS FAMILIARIS; HARNESS;

CANCER; DOG; IMMUNITY; TUMOR STROMA; TYROSINASE; VACCINE;

ANIMAL DISEASES; ANIMALS; ANTIGENS, NEOPLASM; CANCER VACCINES; NEOPLASMS;

EID: 84887613594     PISSN: 10900233     EISSN: 15322971     Source Type: Journal    
DOI: 10.1016/j.tvjl.2013.06.005     Document Type: Review

References (81)

1. Arbyn M., Castellsagué X., de Sanjosé S., Bruni L., Saraiya M., Bray F., Ferlay J. Worldwide burden of cervical cancer in 2008. Annals of Oncology 2011, 22:2675-2686.
2. Balkwill F., Charles K.A., Mantovani A. Smoldering and polarized inflammation in the initiation and promotion of malignant disease. Cancer Cell 2005, 7:211-217.
3. Barquet N., Domingo P. Smallpox: The triumph over the most terrible of the ministers of death. Annals of Internal Medicine 1997, 127:635-642.
4. Ben-Baruch A. Inflammation-associated immune suppression in cancer: The roles played by cytokines, chemokines, and additional mediators. Seminars in Cancer Biology 2006, 16:38-52.
5. Bennett W.T., Pandolfi F., Grove B.H., Hawes G.E., Boyle L.A., Kradin R.L., Kurnick J.T. Dominant rearrangements among human tumor-infiltrating lymphocytes: analysis of T-cells derived from 32 patients with melanoma, lung, and renal cell carcinoma. Cancer 1992, 69:2379-2384.
6. Bergman P.J. Canine oral melanoma. Clinical Techniques in Small Animal Practice 2007, 22:55-60.
7. Bergman P.J., Camps-Palau M.A., McKnight J.A., Leibman N.F., Craft D.M., Leung C., Liao J., Rivière I., Sadelain M., Hohenhaus A.E., et al. Development of a xenogeneic DNA vaccine program for canine malignant melanoma at the Animal Medical Center. Vaccine 2006, 24:4582-4585.
8. Bhowmick N.A., Chytil A., Plieth D., Gorska A.E., Dumont N., Shappell S., Washington M.K., Neilson E.G., Moses H.L. TGF-beta signaling in fibroblasts modulates the oncogenic potential of adjacent epithelia. Science 2004, 303:848-851.
9. Boghossian S., Robinson S., Von Delwig A., Manas D., White S. Immunotherapy for treating metastatic colorectal cancer. Surgical Oncology 2011, 21:67-77.
10. Briest F., Berndt A., Clement J., Junker K., Eggeling F., Grimm S., Friedrich K. Tumor-stroma interactions in tumorigenesis: Lessons from stem cell biology. Frontiers in Bioscience (Elite Edition) 2012, 4:1871-1887.
11. Buonaguro L., Petrizzo A., Tornesello M.L., Buonaguro F. Translating tumor antigens into cancer vaccines. Clinical and Vaccine Immunology 2011, 18:23-34.
12. Centers for Disease Control and Prevention (CDC), 2011. Progress Toward Implementation of Human Papillomavirus Vaccination - The Americas, 2006-2010. Morbidity and Mortality Weekly Report 60, pp. 1382-1384.
13. Chow M.T., Möller A., Smyth M.J. Inflammation and immune surveillance in cancer. Seminars in Cancer Biology 2012, 22:23-32.
14. Dougan M., Dranoff G. Immune therapy for cancer. Annual Review of Immunology 2009, 27:83-117.
15. Dranoff G. Cytokines in cancer pathogenesis and cancer therapy. Nature Reviews Cancer 2004, 4:11-22.
16. Dunn G.P., Bruce A.T., Ikeda H., Old L.J., Schreiber R.D. Cancer immunoediting: From immunosurveillance to tumor escape. Nature Immunology 2002, 3:991-998.
17. Dunn G.P., Old L.J., Schreiber R.D. The three Es of cancer immunoediting. Annual Review of Immunology 2004, 22:329-360.
18. Dunn I.S., Haggerty T.J., Kono M., Durda P.J., Butera D., Macdonald D.B., Benson E.M., Rose L.B., Kurnick J.T. Enhancement of human melanoma antigen expression by IFN-β. Journal of Immunology 2007, 179:2134-2142.
19. Ehrlich P. Ueber den jetzigen stand der Karzinomforschung. Nederlands tijdschrift voor geneeskunde 1909, 5:273-290.
20. Einstein M.H., Baron M., Levin M.J., Chatterjee A., Fox B., Scholar S., Rosen J., Chakhtoura N., Meric D., Dessy F.J., et al. Comparative immunogenicity and safety of human papillomavirus (HPV)-16/18 vaccine and HPV-6/11/16/18 vaccine. Human Vaccines 2011, 7:1343-1358.
21. Frey A.B., Monu N. Effector-phase tolerance: Another mechanism of how cancer escapes antitumor immune response. Journal of Leukocyte Biology 2006, 79:652-662.
22. Gajewski T.F., Meng Y., Blank C., Brown I., Kacha A., Kline J., Harlin H. Immune resistance orchestrated by the tumor microenvironment. Immunology Reviews 2006, 231:131-145.
23. Ganss R., Arnold B., Hammerling G.J. Overcoming tumor-intrinsic resistance to immune effector function. European Journal of Immunology 2004, 34:2635-2641.
24. Giovannetti A., Pierdominici A.Di., Iorio A., Cianci R., Murdaca G., Puppo F., Pandolfi F., Paganelli R. Apoptosis in the homeostasis of the immune system and in human immune mediated diseases. Current Pharmaceutical Design 2008, 14:253-268.
25. Goutagny N., Estornes Y., Hasan U., Lebecque S., Caux C. Targeting pattern recognition receptors in cancer immunotherapy. Targeted Oncology 2012, 7:29-54.
26. Gridelli C., Rossi A., Maione P., Ferrara M.L., Castaldo V., Sacco P.A. Vaccines for the treatment of non-small cell lung cancer: a renewed anticancer strategy. The Oncologist 2009, 14:909-920.
27. Groscurth P., Filgueira L. Killing mechanisms of cytotoxic T lymphocytes. News in Physiological Sciences 1998, 13:17-21.
28. Hall S.J., Pantuck A.J., George D.J., Whitmore J.B., Frohlich M.W., Sims R.B. Integrated safety data from 4 randomized, double-blind, controlled trials of autologous cellular immunotherapy with sipuleucel-T in patients with prostate cancer. Journal of Urology 2011, 186:877-881.
29. Hamilton E., Blackwell K., Hobeika A.C., Clay T.M., Broadwater G., Ren X.R., Chen W., Castro H., Lehmann F., Spector N., et al. Phase I clinical trial of HER2-specific immunotherapy with concomitant HER2 kinase inhibition. Journal of Translational Medicine 2012, 10:28.
30. Haslam S.Z., Woodward T.L. Host microenvironment in breast cancer development: epithelial-cell-stromal-cell interactions and steroid hormone action in normal and cancerous mammary gland. Breast Cancer Research 2003, 5:208-215.
31. Henning T., Kraus M., Brischwein M., Otto A.M., Wolf B. Relevance of tumor microenvironment for progression, therapy and drug development. Anti-Cancer Drugs 2004, 15:7-14.
32. Hersey P., Menzies S.W., Halliday G.M., Nguyen T., Farrelly M.L., DeSilva C., Lett M. Phase I/II study of treatment with dendritic cell vaccines in patients with disseminated melanoma. Cancer Immunology Immunotherapy 2004, 53:125-134.
33. Hishii M., Andrews D., Boyle L.A., Wong J.T., Pandolfi F., van den Elsen P.J., Kurnick J.T. In vivo accumulation of the same anti-melanoma T cell clone in two different metastatic sites. Proceedings of the National Academy of Sciences of the United States of America 1997, 94:1378-1383.
34. Huang B., Zhao J., Li H., He K.L., Chen Y., Chen S.H., Mayer L., Unkeless J.C., Xiong H. Toll-like receptors on tumor cells facilitate evasion of immune surveillance. Cancer Research 2005, 66:5009-5014.
35. Inogés S., de Cerio A.L., Villanueva H., Soria E., Pastor F., Bendandi M. Idiotype vaccines for lymphoma therapy. Expert Review of Vaccines 2011, 10:801-809.
36. Iwasaki A., Medzhitov R. Toll-like receptor control of the adaptive immune responses. Nature Immunology 2004, 5:987-995.
37. Kantoff P.W., Higano C.S., Shore N.D., Berger E.R., Small E.J., Penson D.F., Redfern C.H., Ferrari A.C., Dreicer R., Sims R.B., Xu Y., Frohlich M.W., Schellhammer P.F. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. New England Journal of Medicine 2010, 363:411-422.
38. Kelly M.G., Alvero A.B., Chen R., Silasi D.A., Abrahams V.M., Chan S., Visintin I., Rutherford T., Mor G. TLR-4 signaling promotes tumor growth and paclitaxel chemoresistance in ovarian cancer. Cancer Research 2006, 66:3859-3868.
39. Lim S.H., Zhang Y., Zhang J. Cancer-testis antigens: The current status on antigen regulation and potential clinical use. American Journal of Blood Research 2012, 2:29-35.
40. Lu H., Goodell V., Disis M. Humoral immunity directed against tumor-associated antigens as potential biomarkers for the early diagnosis of cancer. Journal of Proteome Research 2008, 7:1388-1394.
41. Lutz E., Yeo C.J., Lillemoe K.D., Biedrzycki B., Kobrin B., Herman J., Sugar E., Piantadosi S., Cameron J.L., Solt S., et al. A lethally irradiated allogeneic granulocyte-macrophage colony stimulating factor-secreting tumor vaccine for pancreatic adenocarcinoma. A Phase II trial of safety, efficacy, and immune activation. Annals of Surgery 2011, 253:328-335.
42. Manley C.A., Leibman N.F., Wolchok J.D., Rivière I.C., Bartido S., Craft D.M., Bergman P.J. Xenogeneic murine tyrosinase DNA vaccine for malignant melanoma of the digit of dogs. Journal of Veterinary Internal Medicine 2011, 25:94-99.
43. Mantovani A., Cassatella M.A., Costantini C., Jaillon S. Neutrophils in the activation and regulation of innate and adaptive immunity. Nature Reviews Immunology 2011, 11:519-531.
44. Marino D.J., Matthiesen D.T., Stefanacci J.D., Moroff S.D. Evaluation of dogs with digit masses: 117 cases (1981-1991). Journal of the American Veterinary Medical Association 1995, 207:726-728.
45. Mazurek U., Owczarek A., Nowakowska-Zajdel E., Wierzgon J., Grochowska-Niedworok E., Kokot T., Muc-Wierzgon M. Statistical analysis of differential gene expression in colorectal cancer using clear-test. Journal of Biological Regulators and Homeostatic Agents 2011, 25:279-283.
46. Melenhorst J.J., Barrett A.L. Tumor vaccines and beyond. Cytotherapy 2011, 13:8-18.
47. Meulmeester E., ten Dijke P. The dynamic roles of TGF-β in cancer. Journal of Pathology 2011, 223:205-218.
48. Ning N., Pan Q., Zheng F., Teitz-Tennenbaum S., Egenti M., Yet J., Li M., Ginestier C., Wicha M.S., Moyer J.S., et al. Cancer stem cell vaccination confers significant antitumor immunity. Cancer Research 2012, 72:1853-1864.
49. Onizuka S., Tawara I., Shimizu J., Sakaguchi S., Fujita T., Nakayama E. Tumor rejection by in vivo administration of anti-CD25 (interleukin-2 receptor) monoclonal antibody. Cancer Research 1999, 59:3128-3133.
50. Ostrand-Rosenberg S., Sinha P. Myeloid-derived suppressor cells: Linking inflammation and cancer. Journal of Immunology 2009, 182:4499-4506.
51. Palma G., De Laurenzi V., De Marco M., Barbieri A., Petrillo A., Turco M.C., Arra C. Plasmacytoids dendritic cells are a therapeutic target in anticancer immunity. Biochimica et Biophysica Acta 2012, 1826:407-414.
52. Pandolfi F., Cianci R., Lolli S., Dunn I.S., Newton E.E., Haggerty T.J., Boyle L.A., Kurnick J.T. Strategies to overcome obstacles to successful immunotherapy of melanoma. International Journal of Immunopathology and Pharmacology 2008, 21:493-500.
53. Perdrizet G.A., Ross S.R., Stauss H.J., Singh S., Koeppen H., Schreiber H. Animals bearing malignant grafts reject normal grafts that express through gene transfer the same antigen. Journal of Experimental Medicine 1990, 171:1205-1220.
54. Placke T., Salih H.R., Kopp H.-G. GITR ligand provided by thromobopoietic cells Inhibits NK cell antitumor activity. The Journal of Immunology 2012, 189:154-160.
55. Räsänen K., Vaheri A. Activation of fibroblasts in cancer stroma. Experimental Cell Research 2010, 316:2713-2722.
56. Reed J.C. Mechanisms of apoptosis avoidance in cancer. Current Opinion in Oncology 1999, 11:68-75.
57. Rippo M.R., Villanova F., Tomassoni Ardori F., Graciotti L., Amatori S., Manzotti S., Fanelli M., Gigante A., Procopio A. Dexamethasone affects Fas- and serum deprivation-induced cell death of human osteoblastic cells through surviving regulation. International Journal of Immunopathology and Pharmacology 2010, 23:1153-1165.
58. Sasada T., Kimura M., Yoshida Y., Kanai M., Takabayashi A. CD4+CD25+ regulatory T cells in patients with gastrointestinal malignancies: Possible involvement of regulatory T cells in disease progression. Cancer 2003, 98:1089-1099.
59. Schlom J. Therapeutic cancer vaccines: Current status and moving forward. Journal of the National Cancer Institute 2012, 104:599-613.
60. Schor S.L., Scor A.M. Phenotypic and genetic alterations in mammary stroma: Implications for tumour progression. Breast Cancer Research 2001, 3:373-379.
61. Schwartzentruber D.J., Lawson D.H., Richards J.M., Conry R.M., Miller D.M., Treisman J., Gailani F., Riley L., Conlon K., Pockaj B., et al. Gp100 peptide vaccine and interleukin-2 in patients with advanced melanoma. New England Journal of Medicine 2011, 364:2119-2127.
62. Schwarz T.F. Clinical update of the AS04-advuvanted human papillomavirus-16/18 cervical cancer vaccine, Cervarix®. Advances in Therapy 2009, 26:983-998.
63. Shekhar M.P., Werdell J., Santner S.J., Pauley R.J., Tait L. Breast stroma plays a dominant regulatory role in breast epithelial growth and differentiation: Implications for tumor development and progression. Cancer Research 2001, 61:1320-1326.
64. + T cells: A common basis between tumor immunity and autoimmunity. Journal of Immunology 1999, 163:5211-5218.
65. Silze T., Randolph G.J., Kreutz M., Kunz-Schughart L.A. The fibroblast: Sentinel cell and local immune modulator in tumor tissue. International Journal of Cancer 2004, 108:173-180.
66. Sims G.P., Rowe D.C., Rietdijk S.T., Herbst R., Coyle A.J. HMGB1 and RAGE in inflammation and cancer. Annual Review of Immunology 2009, 28:367-388.
67. Singh S., Ross S.R., Acena M., Rowley D.A., Schreiber H. Stroma is critical for preventing or permitting immunological destruction of antigenic cancer cells. Journal of Experimental Medicine 1992, 175:139-146.
68. Slingluff C.L., Petroni G.R., Olson W., Czarkowski A., Grosh W.W., Smolkin M., Chianese-Bullock K.A., Neese P.Y., Deacon D.H., Nail C., et al. Helper T-cell responses and clinical activity of a melanoma vaccine with multiple peptides from MAGE and melanocytic differentiation antigens. Journal of Clinical Oncology 2008, 26:4973-4980.
69. Spangler W.L., Kass P.H. The histologic and epidemiologic bases for prognostic considerations in canine melanocytic neoplasia. Veterinary Pathology 2006, 43:136-149.
70. Suckow M.A., Wolter W.R., Pollard M. Prevention of de novo prostate cancer by immunization with tumor-derived vaccines. Cancer Immunology Immunotherapy 2005, 54:571-576.
71. Suckow M.A., Heinrich J., Rosen E.D. Tissue vaccines for cancer. Expert Review of Vaccines 2007, 6:925-937.
72. Suckow M.A., Wolter W.R., Sailes V.T. Inhibition of prostate cancer metastasis by administration of a tissue vaccine. Clinical and Experimental Metastasis 2008, 25:913-918.
73. Suckow M.A., Wheeler J., Wolter W.R., Sailes V., Yan M. Immunization with a tissue vaccine enhances the effect of irradiation on prostate tumors. In Vivo 2008, 22:171-178.
74. Suckow M.A., Hall P., Wolter W., Sailes V., Hiles M.C. Use of an extracellular matrix material as a vaccine carrier and adjuvant. Anticancer Research 2008, 28:2529-2534.
75. Swann J.B., Smyth M.J. Immune surveillance of tumors. Journal of Clinical Investigation 2007, 117:1137-1146.
76. Szczepanski M.J., Czystowska M., Szajnik M., Harasymczuk M., Boyiadzis M., Kruk-Zagajewska A., Szyfter W., Zeromski J., Whiteside T.L. Triggering of Toll-like receptor 4 expressed on human head and neck squamous cell carcinoma promotes tumor development and protects the tumor from immune attack. Cancer Research 2009, 69:3105-3113.
77. Wang Y., Zhou L., Wang H.Y., Xiao J.X., Si L.S., Wang Y.L. The ex vivo microenviroments in MLTC of poorly immunogenic tumor cells facilitate polarization of CD4+CD25+ regulatory T cells. Cellular & Molecular Immunology 2006, 3:123-129.
78. Whiteside T.L. Immune suppression in cancer: Effects on immune cells, mechanism and future therapeutic intervention. Seminars in Cancer Biology 2006, 16:3-15.
79. Woo E.Y., Chu C.S., Goletz T.J., Schlienger K., Yeh H., Coukos G., Rubin S.C., Kaiser L.R., June C.H. Regulatory CD4(+)CD25(+) T cells in tumors from patients with early-stage non-small cell lung cancer and late-stage ovarian cancer. Cancer Research 2001, 61:4766-4772.
80. Yee C., Thompson J.A., Byrd D., Riddell S.R., Roche P., Celis E., Greenberg P.D. Adoptive T cell therapy using antigenspecific CD[8] T cell clones for the treatment of patients with metastatic melanoma: In vivo persistence, migration, and antitumor effect of transferred T cells. Proceedings of the National Academy of Science of the United States of America 2002, 99:16168-16173.
81. Zou W. Regulatory T cells, tumour immunity and immunotherapy. Nature Reviews Immunology 2006, 6:295-307.